Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 780-787

  Harousseau, J L ^a   Witz, B ^a   Lioure, B ^a   Hunault Berger, M ^a   Desablens, B ^a   Delain, M ^a   Guilhot, F ^a   Le Prise, P Y ^a   Abgrall, J F ^a   Deconinck, E ^a   Guyotat, D ^a   Vilque, J P ^a   Casassus, P ^a   Tournilhac, O ^a   Audhuy, B ^a   Solary, E ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033957073     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.780     Document Type: Article

References (30)

1. Burnett AK: Transplantation in first remission of acute myeloid leukemia. N Engl J Med 339:1698-1700, 1998
2. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
3. Gorin NC: Autologous stem cell transplantation in acute myelocytic leukemia. Blood 92:1073-1090, 1998
4. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
5. Burnett A, Goldstone AH, Stevens RMF, et al: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 351:700-707, 1998
6. Ravindranath Y, Yeager AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428-1434, 1996
7. Harousseau JL, Cahn JY, Pignon B, et al: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90:2978-2986, 1997
8. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
9. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675-3685, 1996
10. Terpstra W, Lowenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11:315-327, 1997
11. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 11:328-341, 1997
12. Harousseau JL: The role of colony stimulating factors in the treatment of acute leukemia. Biodrugs 6:448-460, 1997
13. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative group. Ann Intern Med 103:626-629, 1985
14. Dastugue N, Payen C, Lafage-Pochitaloff M, et al: Prognostic significance of Karyotype in de novo adult myeloid leukemia. Leukemia 9:1491-1498, 1995
15. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
16. Solary E, Witz B, Caillot D, et al: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88:1198-1205, 1996
17. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 232:1678-1683, 1995
18. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 86:457-462, 1995
19. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
20. Heil G, Hoelzer D, Sanz MA, et al: A randomized double blind placebo-controlled phase in study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710-4718, 1997
21. Godwin JE, Kosecky KJ, Head DR: A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A South-West Oncology Group Study. Blood 91:3607-3615, 1998
22. Zittoun R, Suciu S, Mandelli F, et al: Granulocyte macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150-2159, 1996
23. Lowenberg B, Suciu S, Archimbaud E, et al: Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 90:2952-2961, 1997
24. Lowenberg B, Boogaerts MA, Daenen SMGJ, et al: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496-3506, 1997
25. Witz F, Sadoun A, Perrin MC, et al: A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 91:2722-2730, 1998
26. Moore JO, Dodge RK, Amrein PC, et al: Granulocyte colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoguinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 89:780-788, 1997
27. Reiffers J, Korbling M, Labopin M, et al: Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first remission. Int J Cell Cloning 10:111-113, 1992
28. Sanz MA, de La Rubia J, Sanz GF, et al: Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients in first complete remission: A report from a single institution. J Clin Oncol 11:1661-1667, 1993
29. Demirer T, Petersen FB, Bensinger WI, et al: Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplant 18:29-34, 1996
30. Martin C, Torres A, Leon A, et al: Autologous peripheral blood stem cell transplantation mobilized with G-CSF in AML in first complete remission: Role of intensification therapy in outcome. Bone Marrow Transplant 21:375-382, 1998